Clinical Trials in Tennessee

Showing 10641-10660 of 20,239 trials

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061

We will need about 36 participants for this study. Volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good for them * 12 weeks of treatment with Acthar gel * 4 weeks to wean off Acthar gel and follow-up with the doctor

Keratitis

Mallinckrodt36 participantsStarted Nov 2019

Phoenix, Arizona, United States • Glendale, California, United States • Newport Beach, California, United States +6 more locations

TERMINATEDPhase 229 miles

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

NCT00435227

This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory tract of children who present with RSV illness but who do not require hospitalization. Using 1:1 randomization, 30 mg/kg motavizumab or placebo will be administered as soon as possible after a child's diagnosis of RSV and his/her eligibility for the study has been confirmed.

Participants Less Than 12 Months of Age With RSV Illness

MedImmune LLC12 participantsStarted Mar 2007

Tucson, Arizona, United States • Jonesboro, Arkansas, United States • Jonesboro, Arkansas, United States +28 more locations

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Find Trials by Condition in Tennessee

Effects of Lifestyle Modification on Vestibular Migraine

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

Study of Octanorm Subcutaneous IG in Patients With PID

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

CMX001 in Post-transplant Patients With BK Virus Viruria

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

Anorectal Microbicide Project(AMP): Rectal Health, Behaviors and Microbicide Acceptability

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma